Name: MC-Val-Cit-PAB-MMAE
Brand: BOC Sciences
Price: 159 USD
Availability: MadeToOrder

Size

Price

Stock

Quantity

1 mg

$159

In stock

Synonyms

VcMMAE; Maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl-monomethyl auristatin E; Vedotin

IUPAC Name

[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate

Canonical SMILES

CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(C)C(C2=CC=CC=C2)O)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)N(C)C(=O)OCC3=CC=C(C=C3)NC(=O)C(CCCNC(=O)N)NC(=O)C(C(C)C)NC(=O)CCCCCN4C(=O)C=CC4=O

InChI

InChI=1S/C68H105N11O15/c1-15-43(8)59(51(92-13)38-55(83)78-37-23-27-50(78)61(93-14)44(9)62(85)71-45(10)60(84)47-24-18-16-19-25-47)76(11)66(89)57(41(4)5)75-65(88)58(42(6)7)77(12)68(91)94-39-46-29-31-48(32-30-46)72-63(86)49(26-22-35-70-67(69)90)73-64(87)56(40(2)3)74-52(80)28-20-17-21-36-79-53(81)33-34-54(79)82/h16,18-19,24-25,29-34,40-45,49-51,56-61,84H,15,17,20-23,26-28,35-39H2,1-14H3,(H,71,85)(H,72,86)(H,73,87)(H,74,80)(H,75,88)(H3,69,70,90)/t43-,44+,45+,49-,50-,51+,56-,57-,58-,59-,60+,61+/m0/s1

InChIKey

NLMBVBUNULOTNS-HOKPPMCLSA-N

Sequence

VXXVV

Density

1.2±0.1 g/cm3

Solubility

Soluble in DMSO, ethanol; insoluble in water

Flash Point

768.8±34.3 °C

Index Of Refraction

1.556

Vapor Pressure

0.0±0.3 mmHg at 25°C

Appearance

Solid Powder

Shipping

Room temperature, or blue ice upon request.

Storage

2 - 8 °C

Pictograms

Irritant; Acute Toxic

Signal Word

Danger

Boiling Point

1347.6±65.0 °C at 760 mmHg

1.Cathepsin B Cleavage of vcMMAE-Based Antibody-Drug Conjugate Is Not Drug Location or Monoclonal Antibody Carrier Specific.

Gikanga B1, Adeniji NS1, Patapoff TW1, Chih HW1, Yi L1. Bioconjug Chem. 2016 Apr 20;27(4):1040-9. doi: 10.1021/acs.bioconjchem.6b00055. Epub 2016 Mar 10.

Antibody-drug conjugates (ADCs) require thorough characterization and understanding of product quality attributes. The framework of many ADCs comprises one molecule of antibody that is usually conjugated with multiple drug molecules at various locations. It is unknown whether the drug release rate from the ADC is dependent on drug location, and/or local environment, dictated by the sequence and structure of the antibody carrier. This study addresses these issues with valine-citrulline-monomethylauristatin E (vc-MMAE)-based ADC molecules conjugated at reduced disulfide bonds, by evaluating the cathepsin B catalyzed drug release rate of ADC molecules with different drug distributions or antibody carriers. MMAE drug release rates at different locations on ADC I were compared to evaluate the impact of drug location. No difference in rates was observed for drug released from the VH, VL, or CH2 domains of ADC I. Furthermore, four vc-MMAE ADC molecules were chosen as substrates for cathepsin B for evaluation of Michaelis-Menten parameters.

HPLC

Catalog	Product Name	CAS
BADC-00019	Fmoc-VC-PAB-MMAE	1350456-56-2
BADC-00849	Acetylene-linker-Val-Cit-PABC-MMAE	1411977-95-1
BADC-01448	mDPR-Val-Cit-PAB-MMAE	1491152-26-1
BADC-00958	Amino-PEG4-Val-Cit-PAB-MMAE	1492056-71-9
BADC-01348	Val-Cit-PAB-MMAE TFA salt	1608127-32-7
BADC-01435	N-Ac-Cys-MC-VC-PAB-MMAE	1628933-80-1
BADC-01408	DBM(C6)-VC-PAB-MMAE	1644228-55-6
BADC-01459	MC-betaglucuronide-MMAE-1	1703778-92-0
BADC-01638	OH-Glu-Val-Cit-PAB-MMAE	1895916-23-0
BADC-00855	SuO-Glu-Val-Cit-PAB-MMAE	1895916-24-1